Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
$4.26
-$0.11(-2.78%)
At close: 4:00 PM EST
$4.26
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$1.61 - $9.50
Previous CloseN/A
Volume147.46K
Average Volume (3M)3.75M
Market Cap
$364.62M
Enterprise Value$51.13M
Total Cash (Recent Filing)$138.52M
Total Debt (Recent Filing)$4.61M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Nov 18, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding85,590,390
10 Day Avg. Volume3,318,504
30 Day Avg. Volume3,746,105
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue106.08
Enterprise Value/Gross Profit-6.39K
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$17.25Price Target Upside304.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Clinical TrialsFunctional improvement from baseline on clinical endpoints was observed with nomlabofusp treatment out to one year, which is divergent from FA-COMS natural history and has not been observed before in an FA interventional trial.
EarningsPalynziq has experienced consistent sales growth since launch, generating ~$87M in annual sales in its first full year of launch, at a ~$400M run rate.
Regulatory PathwayA written correspondence from the FDA provides a clearer path toward achieving the goal of filing under an accelerated approval pathway.
Bears Say
Clinical DataReported patient numbers appearing to be less than the 30 to 40 patients worth of data that was previously guided to.
Market ReactionLarimar shares are down about 30%, related to commentary regarding the tolerability profile of nomlabofusp and the resultant protocol change.
Safety ConcernsAnaphylaxis-related symptoms (7 confirmed cases) have raised investor concerns and triggered a change in treatment protocol.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $9.50 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $364.62M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 32 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.48 by $0.07.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.4.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 85,590,390 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.48. Following the earnings report the stock price went up 14.516%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
Larimar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.25 (304.93% Upside)
$17.25 (304.93% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 249.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 30.8%
Last 30 Days ▲ 30.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.74%
12-Months-Change
Fundamentals
Return on Equity
-60.25%
Trailing 12-Months
Asset Growth
-36.76%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (LRMR) is a clinical-stage biotechnology company focused on developing treatments for rare, complex diseases. The company is headquartered in the United States and operates within the pharmaceutical and biotechnology sectors. Its core product is CTI-1601, a novel protein replacement therapy designed to address Friedreich's ataxia, a debilitating genetic disorder. Larimar Therapeutics is committed to advancing its pipeline of therapeutics to improve the lives of patients with unmet medical needs.
LRMR Stock 12 Month Forecast
Average Price Target
$17.25
▲(304.93% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
35.39% Insiders
5.32% Mutual Funds
0.43% Other Institutional Investors
52.44% Public Companies and Individual Investors